Business
Cosmos Health Announces Successful EN 12791 Study Results for C-Scrub Wash 4%, Strengthening Expansion into Hospital and Surgical Markets
CHICAGO, IL / ACCESS Newswire / April 1, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated
About this update from Cosmos Health Inc.
[{"type":"text","content":"CHICAGO, IL / ACCESS Newswire / April 1, 2026 / Cosmos Health Inc. (\"Cosmos Health\" or the \"Company\") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that C-Scrub Wash 4%, manufactured by its wholly owned subsidiary Cana Laboratories S.A., has successfully completed testing under EN 12791:2016+A1:2017, the European standard for surgical hand disinfection.The independent study, conducted by Quality Assurance & Control Systems Ltd. (QACS), a Greece-based testing and certification laboratory specializing in microbiological and disinfectant efficacy studies, confirmed that C-Scrub Wash 4% demonstrated effective antimicrobial activity for surgical hand disinfection in accordance with EN 12791 requirements. The product is formulated with 4% Chlorhexidine Digluconate and is designed for use in healthcare and clinical environments requiring high standards of hygiene and infection prevention.EN 12791 is a widely recognized European benchmark for surgical hand antisepsis products and supports entry into hospital, surgical, and professional healthcare channels. The Company believes that successful completion of this study strengthens the clinical positioning of C-Scrub Wash 4% and opens additional commercial opportunities across international healthcare markets.This milestone comes as C-Scrub continues gaining traction across several key markets, including the United Kingdom, where Cosmos Health has recently announced expanding commercial availability and growing market presence. The Company believes the EN 12791 study completion further supports its strategy to expand the C-Scrub portfolio across both retail and institutional healthcare channels.The Company believes that this achievement further strengthens Cosmos Health's infection control portfolio, enhances the commercial positioning of the C-Scrub brand, and supports continued international growth.Greg Siokas, CEO of Cosmos Health, stated: \"The successful completion of the EN 12791 study for C-Scrub Wash 4% represents an important milestone for Cosmos Health. As demand for infection control solutions continues to grow across key markets, this achievement enhances the clinical credibility of our C-Scrub portfolio and supports expansion into hospital, surgical, and institutional healthcare markets globally. By achieving technical parity ...